Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Cellular and Metabolic Basis for the Ichthyotic Phenotype in NIPAL4 (Ichthyin)-Deficient Canines

EA. Mauldin, D. Crumrine, ML. Casal, S. Jeong, L. Opálka, K. Vavrova, Y. Uchida, K. Park, B. Craiglow, KA. Choate, KO. Shin, YM. Lee, GL. Grove, JS. Wakefield, D. Khnykin, PM. Elias,

. 2018 ; 188 (6) : 1419-1429. [pub] 20180313

Language English Country United States

Document type Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19035347

Grant support
P40 OD010939 NIH HHS - United States
R01 AR061106 NIAMS NIH HHS - United States
R01 AR068392 NIAMS NIH HHS - United States

Mutations in several lipid synthetic enzymes that block fatty acid and ceramide production produce autosomal recessive congenital ichthyoses (ARCIs) and associated abnormalities in permeability barrier homeostasis. However, the basis for the phenotype in patients with NIPAL4 (ichthyin) mutations (among the most prevalent ARCIs) remains unknown. Barrier function was abnormal in an index patient and in canines with homozygous NIPAL4 mutations, attributable to extensive membrane stripping, likely from detergent effects of nonesterified free fatty acid. Cytotoxicity compromised not only lamellar body secretion but also formation of the corneocyte lipid envelope (CLE) and attenuation of the cornified envelope (CE), consistent with a previously unrecognized, scaffold function of the CLE. Together, these abnormalities result in failure to form normal lamellar bilayers, accounting for the permeability barrier abnormality and clinical phenotype in NIPA-like domain-containing 4 (NIPAL4) deficiency. Thus, NIPAL4 deficiency represents another lipid synthetic ARCI that converges on the CLE (and CE), compromising their putative scaffold function. However, the clinical phenotype only partially improved after normalization of CLE and CE structure with topical ω-O-acylceramide because of ongoing accumulation of toxic metabolites, further evidence that proximal, cytotoxic metabolites contribute to disease pathogenesis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035347
003      
CZ-PrNML
005      
20191015115535.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ajpath.2018.02.008 $2 doi
035    __
$a (PubMed)29548991
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Mauldin, Elizabeth A $u Department of Dermatopathology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
245    10
$a Cellular and Metabolic Basis for the Ichthyotic Phenotype in NIPAL4 (Ichthyin)-Deficient Canines / $c EA. Mauldin, D. Crumrine, ML. Casal, S. Jeong, L. Opálka, K. Vavrova, Y. Uchida, K. Park, B. Craiglow, KA. Choate, KO. Shin, YM. Lee, GL. Grove, JS. Wakefield, D. Khnykin, PM. Elias,
520    9_
$a Mutations in several lipid synthetic enzymes that block fatty acid and ceramide production produce autosomal recessive congenital ichthyoses (ARCIs) and associated abnormalities in permeability barrier homeostasis. However, the basis for the phenotype in patients with NIPAL4 (ichthyin) mutations (among the most prevalent ARCIs) remains unknown. Barrier function was abnormal in an index patient and in canines with homozygous NIPAL4 mutations, attributable to extensive membrane stripping, likely from detergent effects of nonesterified free fatty acid. Cytotoxicity compromised not only lamellar body secretion but also formation of the corneocyte lipid envelope (CLE) and attenuation of the cornified envelope (CE), consistent with a previously unrecognized, scaffold function of the CLE. Together, these abnormalities result in failure to form normal lamellar bilayers, accounting for the permeability barrier abnormality and clinical phenotype in NIPA-like domain-containing 4 (NIPAL4) deficiency. Thus, NIPAL4 deficiency represents another lipid synthetic ARCI that converges on the CLE (and CE), compromising their putative scaffold function. However, the clinical phenotype only partially improved after normalization of CLE and CE structure with topical ω-O-acylceramide because of ongoing accumulation of toxic metabolites, further evidence that proximal, cytotoxic metabolites contribute to disease pathogenesis.
650    _2
$a dospělí $7 D000328
650    _2
$a zvířata $7 D000818
650    12
$a modely nemocí na zvířatech $7 D004195
650    _2
$a psi $7 D004285
650    _2
$a epidermis $x metabolismus $x patologie $7 D004817
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a homozygot $7 D006720
650    _2
$a lidé $7 D006801
650    _2
$a ichtyóza $x genetika $x metabolismus $x patologie $7 D007057
650    _2
$a lipidy $x analýza $7 D008055
650    _2
$a mužské pohlaví $7 D008297
650    12
$a mutace $7 D009154
650    _2
$a rodokmen $7 D010375
650    _2
$a fenotyp $7 D010641
650    _2
$a receptory buněčného povrchu $x nedostatek $x genetika $7 D011956
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Crumrine, Debra $u Dermatology Service, Veterans Affairs Medical Center, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.
700    1_
$a Casal, Margret L $u Department of Dermatopathology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
700    1_
$a Jeong, Sekyoo $u Department of BioCosmetics, Seowon University, Cheongju, South Korea.
700    1_
$a Opálka, Lukáš $u Department of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Vavrova, Katerina $u Department of BioCosmetics, Seowon University, Cheongju, South Korea; Department of Pharmacy, Charles University, Hradec Kralove, Czech Republic.
700    1_
$a Uchida, Yoshikazu $u Dermatology Service, Veterans Affairs Medical Center, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.
700    1_
$a Park, Kyungho $u Dermatology Service, Veterans Affairs Medical Center, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.
700    1_
$a Craiglow, Brittany $u Department of Pharmacy, Charles University, Hradec Kralove, Czech Republic; Department of Dermatology, Genetics, and Pathology, Yale University, New Haven, Connecticut.
700    1_
$a Choate, Keith A $u Department of Pharmacy, Charles University, Hradec Kralove, Czech Republic; Department of Dermatology, Genetics, and Pathology, Yale University, New Haven, Connecticut.
700    1_
$a Shin, Kyong-Oh $u College of Pharmacy, Chungbuk Natl University, Cheongju, South Korea.
700    1_
$a Lee, Yong-Moon $u College of Pharmacy, Chungbuk Natl University, Cheongju, South Korea.
700    1_
$a Grove, Gary L $u Department of Research and Development, cyberDERM, Media, Pennsylvania.
700    1_
$a Wakefield, Joan S $u Dermatology Service, Veterans Affairs Medical Center, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California.
700    1_
$a Khnykin, Denis $u Department of Pathology, Oslo University Hospital, Oslo, Norway.
700    1_
$a Elias, Peter M $u Dermatology Service, Veterans Affairs Medical Center, San Francisco, California; Department of Dermatology, University of California, San Francisco, San Francisco, California. Electronic address: peter.elias@ucsf.edu.
773    0_
$w MED00009121 $t The American journal of pathology $x 1525-2191 $g Roč. 188, č. 6 (2018), s. 1419-1429
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29548991 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015120000 $b ABA008
999    __
$a ok $b bmc $g 1452007 $s 1073897
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 188 $c 6 $d 1419-1429 $e 20180313 $i 1525-2191 $m American journal of pathology $n Am J Pathol $x MED00009121
GRA    __
$a P40 OD010939 $p NIH HHS $2 United States
GRA    __
$a R01 AR061106 $p NIAMS NIH HHS $2 United States
GRA    __
$a R01 AR068392 $p NIAMS NIH HHS $2 United States
LZP    __
$a Pubmed-20191007

Find record

Citation metrics

Archiving options